<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>NASH Article</title>
    <!-- BS CSS Stylesheet -->
    <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.1/dist/css/bootstrap.min.css" rel="stylesheet" integrity="sha384-4bw+/aepP/YC94hEpVNVgiZdgIC5+VKNBQNGCHeKRQN+PtmoHDEXuppvnDJzQIu9" crossorigin="anonymous">
    <link rel="stylesheet" href="style.css">
    <!-- BS JS Stylesheet -->
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.0.2/dist/js/bootstrap.bundle.min.js" integrity="sha384-MrcW6ZMFYlzcLA8Nl+NtUVF0sA7MsXsP1UyJoMp4YLEuNSfAP+JcXn/tWtIaxVXM" crossorigin="anonymous" defer></script>

</head>

<body>
    <nav class="navbar navbar-expand-md bg-dark">
        <div class="container navbar-dark">
            <a href="index.html" class="navbar-brand"><svg xmlns="http://www.w3.org/2000/svg" width="20" height="20" fill="currentColor" class="bi bi-virus" viewBox="0 0 16 16">
                    <path d="M8 0a1 1 0 0 1 1 1v1.402c0 .511.677.693.933.25l.7-1.214a1 1 0 0 1 1.733 1l-.701 1.214c-.256.443.24.939.683.683l1.214-.701a1 1 0 0 1 1 1.732l-1.214.701c-.443.256-.262.933.25.933H15a1 1 0 1 1 0 2h-1.402c-.512 0-.693.677-.25.933l1.214.701a1 1 0 1 1-1 1.732l-1.214-.7c-.443-.257-.939.24-.683.682l.701 1.214a1 1 0 1 1-1.732 1l-.701-1.214c-.256-.443-.933-.262-.933.25V15a1 1 0 1 1-2 0v-1.402c0-.512-.677-.693-.933-.25l-.701 1.214a1 1 0 0 1-1.732-1l.7-1.214c.257-.443-.24-.939-.682-.683l-1.214.701a1 1 0 1 1-1-1.732l1.214-.701c.443-.256.261-.933-.25-.933H1a1 1 0 1 1 0-2h1.402c.511 0 .693-.677.25-.933l-1.214-.701a1 1 0 1 1 1-1.732l1.214.701c.443.256.939-.24.683-.683l-.701-1.214a1 1 0 0 1 1.732-1l.701 1.214c.256.443.933.261.933-.25V1a1 1 0 0 1 1-1Zm2 5a1 1 0 1 0-2 0 1 1 0 0 0 2 0ZM6 7a1 1 0 1 0-2 0 1 1 0 0 0 2 0Zm1 4a1 1 0 1 0 0-2 1 1 0 0 0 0 2Zm5-3a1 1 0 1 0-2 0 1 1 0 0 0 2 0Z" />
                </svg></a>
            <button class="navbar-toggler" type="button" data-bs-toggle="collapse" data-bs-target="#nav2">
                <div class="navbar-toggler-icon"></div>
            </button>
            <div class="collapse navbar-collapse" id="nav2">
                <ul class="navbar-nav">
                    <li class="nav-item">
                        <a href="index.html" class="nav-link">HEPION</a>
                    </li>
                    <li class="nav-item">
                        <a href="about.html" class="nav-link">RENCOFILSTAT</a>
                    </li>
                    <li class="nav-item">
                        <a href="article.html" class="nav-link active">NASH ARTICLES</a>
                    </li>
                    <li class="nav-item">
                        <a href="landscape.html" class="nav-link">NASH LANDSCAPE</a>
                    </li>
                    <li class="nav-item">
                        <a href="result.html" class="nav-link">NASH RESULT</a>
                    </li>
                </ul>
            </div>
        </div>
    </nav>
    <br>

    <!-- DIVIDER -->

    <div class="py-4">
        <div class="container">
            <div class="row g-4">

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Lilly Completes Acquisition of Sigilon Therapeutics. Researching and developing encapsulated cell therapies, including SIG-002, for the treatment of type 1 diabetes.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-sigilon-therapeutics" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 14, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Lilly Completes Acquisition of Versanis Bio. The acquisition expands Lilly's portfolio to include Versanis' lead asset, Bimagrumab.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://investor.lilly.com/news-releases/news-release-details/lilly-completes-acquisition-versanis-bio" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 14, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/novo.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Novo Nordisk to acquire Inversago Pharma to develop new therapies for people living with obesity, diabetes and other serious metabolic diseases.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166304" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 10, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/terns.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Terns Achieves Primary Endpoint And All Secondary Endpoints in P2A Duet Trial of THR-B Agonist TERN-501 In NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.ternspharma.com/news-releases/news-release-details/terns-achieves-primary-endpoint-and-all-secondary-endpoints" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 8, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Initiation Of Phase 2B IMPACT Trial Evaluating The Efficacy And Safety Of Pemvidutide In NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-initiation-phase-2b-impact-trial-evaluating" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 1, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Tirzepatide demonstrated significant and superior weight loss compared to placebo in two pivotal studies.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://investor.lilly.com/news-releases/news-release-details/tirzepatide-demonstrated-significant-and-superior-weight-loss" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">July 27, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/madrigal.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Pharmaceuticals: Submission of New Drug Application
                                Seeking Accelerated Approval of Resmetirom for the Treatment of NASH.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/07/17/2705202/0/en/Madrigal-Pharmaceuticals-Completes-Submission-of-New-Drug-Application-Seeking-Accelerated-Approval-of-Resmetirom-for-the-Treatment-of-NASH-with-Liver-Fibrosis.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">July 17, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>


                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/intercept.jpg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Intercept Restructures As Ocaliva's NASH Hopes Met with FDA Rejection.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/06/22/2693358/0/en/Intercept-Receives-Complete-Response-Letter-from-FDA-for-Obeticholic-Acid-as-a-Treatment-for-Pre-Cirrhotic-Fibrosis-due-to-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 22, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/inventiva.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Inventiva announces positive topline results from the
                                investigator-initiated Phase II clinical trial evaluating
                                lanifibranor in patients with T2D and NAFLD.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://inventivapharma.com/wp-content/uploads/2023/06/Inventiva-PR-Cusi-Lani-Topline-Results-EN-06132023.pdf" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 13, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Phase 2B SYMMETRY Cohort D Study Met Safety &
                                Tolerability Endpoints and Significantly Improved
                                Non-Invasive Markers of NASH-Related Disease.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/06/05/2681816/0/en/Akero-Therapeutics-Phase-2b-SYMMETRY-Cohort-D-Study-Met-Safety-Tolerability-Endpoints-and-Showed-Adding-EFX-to-GLP-1-Therapy-Significantly-Improved-Non-Invasive-Markers-of-NASH-Rel.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 5, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Phase 2 ALTITUDE-NASH Trial Achieves Primary and
                                Secondary Endpoints: Improvement in Liver Function and Multiple NASH
                                Biomarkers.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/05/22/2673221/0/en/Hepion-Pharmaceuticals-Phase-2-ALTITUDE-NASH-Trial-Achieves-Primary-and-Secondary-Endpoints-Including-Improvement-in-Liver-Function-and-Multiple-NASH-Biomarkers.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">May 22, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/viking.png" width="200px">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Viking Therapeutics Announces Positive Top-Line Results from Phase 2B
                                VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-announces-positive-top-line-results-from-phase-2b-voyage-study-of-vk2809-in-patients-with-biopsy-confirmed-non-alcoholic-steatohepatitis-nash-301825395.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">May 16, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/ngm.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">NGM Bio Reports First Quarter 2023 Financial Results and Provides Business Highlights, Including Topline ALPINE 4 Data.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-reports-first-quarter-2023-financial-results-and" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">May 4, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Lilly's tirzepatide achieved up to 15.7% weight loss in adults with obesity or overweight and type 2 diabetes in SURMOUNT-2.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://lilly.mediaroom.com/2023-04-27-Lillys-tirzepatide-achieved-up-to-15-7-weight-loss-in-adults-with-obesity-or-overweight-and-type-2-diabetes-in-SURMOUNT-2" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">April 27, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/madrigal.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Receives Breakthrough Therapy Designation from FDA for
                                Resmetirom.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.madrigalpharma.com/news-releases/news-release-details/madrigal-receives-breakthrough-therapy-designation-fda" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">April 18, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/novo.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Aspect Biosystems and Novo Nordisk enter partnership to develop bioprinted tissue therapeutics for diabetes and obesity.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166089" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 12, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Announces Positive End-of-Phase 2 Meeting with the
                                FDA and SYNCHRONY Phase 3 Program for Efruxifermin in NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2023/03/29/2637124/0/en/Akero-Therapeutics-Announces-Positive-End-of-Phase-2-Meeting-with-the-FDA-and-SYNCHRONY-Phase-3-Program-for-Efruxifermin-in-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 29, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Positive Results From Week 24 Interim Analysis Of Pemvidutide MOMENTUM Phase 2 Obesity Trial And 12-Week Phase 1B Type 2 Diabetes Safety Trial.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-results-week-24-interim-analysis" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 21, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/89bio.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">89biO Phase 2B ENLIVEN Trial of Pegozafermin in NASH Achieved High
                                Statistical Significance on Both Primary Histology Endpoints at 24 Weeks.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2023/03/22/2632062/0/en/89bio-s-Phase-2b-ENLIVEN-Trial-of-Pegozafermin-in-Nonalcoholic-Steatohepatitis-NASH-Achieved-High-Statistical-Significance-on-Both-Primary-Histology-Endpoints-with-Weekly-QW-and-Ev.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 22, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Anti-Cancer Potential of Rencofilstat Expanded with Results from
                                Preclinical Multiple Myeloma Studies.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2023/01/18/2591025/0/en/Anti-Cancer-Potential-of-Rencofilstat-Expanded-with-Results-from-Preclinical-Multiple-Myeloma-Studies.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 18, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Anti-Cancer Activity of Rencofilstat in Combination with Proteosome
                                Inhibitors</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/01/10/2586637/0/en/Presentation-of-Preclinical-Study-Highlighting-Anti-Cancer-Activity-of-Rencofilstat-in-Combination-with-Proteosome-Inhibitors.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 10, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/viking.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Viking Therapeutics Announces Completion of Enrollment in Phase 2B
                                VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.prnewswire.com/news-releases/viking-therapeutics-announces-completion-of-enrollment-in-phase-2b-voyage-study-of-vk2809-in-patients-with-biopsy-confirmed-non-alcoholic-steatohepatitis-nash-301716152.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 9, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/madrigal.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Announces Additional Positive Results from the Pivotal Phase 3
                                MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2023/01/06/2584391/0/en/Madrigal-Announces-Additional-Positive-Results-from-the-Pivotal-Phase-3-MAESTRO-NASH-Clinical-Trial-of-Resmetirom-for-the-Treatment-of-NASH-with-Liver-Fibrosis.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 6, 2023</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Completes Enrollment of Phase 2B SYMMETRY Study and
                                Announces Expected 2023 Milestones.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/12/21/2578218/0/en/Akero-Therapeutics-Completes-Enrollment-of-Phase-2b-SYMMETRY-Study-and-Announces-Expected-2023-Milestones.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 21, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Positive Topline Results From 24-Week (12-Week Extension) Trial Of Pemvidutide In Subjects With NAFLD.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-topline-results-24-week-12-week" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 20, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/madrigal.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Announces Positive Topline Results from the Pivotal Phase 3
                                MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2022/12/19/2576163/0/en/Madrigal-Announces-Positive-Topline-Results-from-the-Pivotal-Phase-3-MAESTRO-NASH-Clinical-Trial-of-Resmetirom-for-the-Treatment-of-NASH-and-Liver-Fibrosis.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 19, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Efruxifermin Granted FDA Breakthrough Therapy Designation for NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/12/08/2570081/0/en/Efruxifermin-Granted-FDA-Breakthrough-Therapy-Designation-for-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 8, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Announces Early Completion of Enrollment in
                                Phase 2 ALTITUDE-NASH Liver Function Trial.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/12/05/2567480/0/en/Hepion-Pharmaceuticals-Announces-Early-Completion-of-Enrollment-in-Phase-2-ALTITUDE-NASH-Liver-Function-Trial.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 5, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/terns.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Terns Pharmaceuticals Highlights Results From P1 Clinical Trial of TERN-501 At AASLD THe Liver Meeting® 2022.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.ternspharma.com/news-releases/news-release-details/terns-pharmaceuticals-highlights-results-phase-1-clinical-trial" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">November 4, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/sagimet.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Sagimet Biosciences Announces Positive Interim Phase 2b Clinical Trial Data with Denifanstat, a First-in-Class Fatty Acid Synthase Inhibitor, in Moderate-to-Severe NASH Patients.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-announces-positive-interim-phase-2b-clinical" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">November 3, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Lilly receives U.S. FDA Fast Track designation for tirzepatide for the treatment of adults with obesity, or overweight with weight-related comorbidities.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://lilly.mediaroom.com/2022-10-06-Lilly-receives-U-S-FDA-Fast-Track-designation-for-tirzepatide-for-the-treatment-of-adults-with-obesity,-or-overweight-with-weight-related-comorbidities" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">October 6, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Significant Reductions In Liver Fat Content And Body Weight In 12-Week Phase 1B Clinical Trial Of Pemvidutide In Subjects With NAFLD.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-significant-reductions-liver-fat-content-and" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 14, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics: Phase 2B HARMONY, 50mg and 28mg EFX
                                Achieved Statistical Significance on Primary and Secondary Endpoints after 24
                                Weeks.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/09/13/2514749/0/en/In-Akero-Therapeutics-Phase-2b-HARMONY-Study-Both-the-50mg-and-28mg-EFX-Doses-Achieved-Statistical-Significance-on-Primary-and-Secondary-Histology-Endpoints-after-24-Weeks.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 13, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Announces Initiation of Dosing in Phase 2
                                ALTITUDE-NASH Liver Function Trial.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/09/12/2513995/0/en/Hepion-Pharmaceuticals-Announces-Initiation-of-Dosing-in-Phase-2-ALTITUDE-NASH-Liver-Function-Trial.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 12, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/madrigal.png" class="img-fluid" width="200px">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Pharmaceuticals Initiates the MAESTRO-NASH Outcomes Study
                                Evaluating Resmetirom for the Treatment of Patients with Compensated NASH Cirrhosis.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/08/31/2507570/0/en/Madrigal-Pharmaceuticals-Initiates-the-MAESTRO-NASH-Outcomes-Study-Evaluating-Resmetirom-for-the-Treatment-of-Patients-with-Compensated-NASH-Cirrhosis.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 31, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Announces Initiation of Phase 2B ASCEND-NASH
                                Trial.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/08/31/2507575/0/en/Hepion-Pharmaceuticals-Announces-Initiation-of-Phase-2b-ASCEND-NASH-Trial.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 31, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/89bio.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">89bio Announces Completion of Enrollment in ENLIVEN, the Phase 2B Trial
                                of Pegozafermin for the Treatment of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2022/08/18/2500772/0/en/89bio-Announces-Completion-of-Enrollment-in-ENLIVEN-the-Phase-2b-Trial-of-Pegozafermin-for-the-Treatment-of-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 18, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/intercept.jpg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Intercept Announces Positive Data in Fibrosis due to NASH from a New Analysis of its Phase 3 REGENERATE Study of Obeticholic Acid.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/07/07/2475765/23024/en/Intercept-Announces-Positive-Data-in-Fibrosis-due-to-NASH-from-a-New-Analysis-of-its-Phase-3-REGENERATE-Study-of-Obeticholic-Acid-OCA.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">July 7, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/inventiva.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Inventiva announces the screening of the first patient in
                                LEGEND, a Phase IIa combination trial with lanifibranor and
                                empagliflozin in patients with NASH and T2D.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://inventivapharma.com/wp-content/uploads/2022/07/Inventiva-PR-LEGEND-Screening-initiation-EN-07-07-2022.pdf" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">July 7, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/novo.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Echosens and Novo Nordisk announce partnership to increase awareness and advance early diagnosis of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=121337" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 22, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Receives FDA Orphan Drug Status Designation for
                                Rencofilstat for the Treatment of Hepatocellular Carcinoma.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/06/20/2465336/0/en/Hepion-Pharmaceuticals-Receives-FDA-Orphan-Drug-Status-Designation-for-Rencofilstat-for-the-Treatment-of-Hepatocellular-Carcinoma.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 20, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">FDA approves Lilly's Mounjaro™ (tirzepatide) injection, the first and only GIP and GLP-1 receptor agonist for the treatment of adults with type 2 diabetes.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://lilly.mediaroom.com/2022-05-13-FDA-approves-Lillys-Mounjaro-TM-tirzepatide-injection,-the-first-and-only-GIP-and-GLP-1-receptor-agonist-for-the-treatment-of-adults-with-type-2-diabetes" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">May 13, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Lilly's tirzepatide delivered up to 22.5% weight loss in adults with obesity or overweight in SURMOUNT-1.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://lilly.mediaroom.com/2022-04-28-Lillys-tirzepatide-delivered-up-to-22-5-weight-loss-in-adults-with-obesity-or-overweight-in-SURMOUNT-1" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">April 28, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Initiation Of 48-Week Phase 2 MOMENTUM Trial Of Pemvidutide In Obesity.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-initiation-48-week-phase-2-momentum-trial" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">April 1, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Completes Enrollment of Phase 2B HARMONY Study in
                                Pre-Cirrhotic NASH Patients.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2022/02/08/2380832/0/en/Akero-Therapeutics-Completes-Enrollment-of-Phase-2b-HARMONY-Study-in-Pre-Cirrhotic-NASH-Patients.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">February 8, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/madrigal.png" class="img-fluid" width="200px">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Positive Topline Phase 3 MAESTRO-NAFLD-1: Safe, Well-Tolerated and
                                Provided Statistically Significant Improvements in Key Measures
                                of Liver and Cardiovascular Health.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/01/31/2375613/0/en/Positive-Topline-Phase-3-MAESTRO-NAFLD-1-Data-Demonstrate-Resmetirom-was-Safe-Well-Tolerated-and-Provided-Statistically-Significant-Improvements-in-Key-Measures-of-Liver-and-Cardio.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 31, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces FDA Clearance Of Pemvidutide (ALT-801) IND For Obesity.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-fda-clearance-pemvidutide-alt-801-ind" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 31, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Rencofilstat in Combination with an Immune Checkpoint Inhibitor,
                                Demonstrates Synergistic Anti-Tumor Activity.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2022/01/26/2373431/0/en/Hepion-Pharmaceuticals-Rencofilstat-in-Combination-with-an-Immune-Checkpoint-Inhibitor-Demonstrates-Synergistic-Anti-Tumor-Activity-in-a-Nonclinical-Liver-Cancer-Study.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 26, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/89bio.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">89bio Reports Positive Topline Results from an Expansion Cohort of the
                                Phase 1B/2A Trial of Pegozafermin (BIO89-100) for the Treatment of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2022/01/24/2371986/0/en/89bio-Reports-Positive-Topline-Results-from-an-Expansion-Cohort-of-the-Phase-1b-2a-Trial-of-Pegozafermin-BIO89-100-for-the-Treatment-of-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 24, 2022</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Announces FDA Clearance of IND Application for
                                CRV431 in the Treatment of Liver Cancer.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/12/21/2356053/0/en/Hepion-Pharmaceuticals-Announces-FDA-Clearance-of-IND-Application-for-CRV431-in-the-Treatment-of-Liver-Cancer.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 21, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/inventiva.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Inventiva announces positive results of clinical thorough QT
                                study conducted with lanifibranor.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://inventivapharma.com/wp-content/uploads/2021/12/Inventiva-PR-TQT-study-EN-6-12-2021.pdf" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">December 6, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Receives FDA Fast Track Designation for CRV431
                                for the Treatment of NASH.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/11/30/2343013/0/en/Hepion-Pharmaceuticals-Receives-FDA-Fast-Track-Designation-for-CRV431-for-the-Treatment-of-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">November 30, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals and FibroFind Announce Anti-Cancer Activity of
                                CRV431 in a Nonclinical Liver Cancer Study.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/11/16/2335363/0/en/Hepion-Pharmaceuticals-and-FibroFind-Announce-Anti-Cancer-Activity-of-CRV431-in-a-Nonclinical-Liver-Cancer-Study.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">November 16, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/sagimet.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">New Data from Sagimet's Phase 2 FASCINATE-1 Clinical Trial Demonstrate TVB-2640's Positive Effect Across Patients with NASH in the U.S. and China.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.sagimet.com/news-releases/news-release-details/new-data-sagimets-phase-2-fascinate-1-clinical-trial-demonstrate" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">November 12, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/terns.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Terns Reports Positive Top-Line Results From P1 Proof Of Concept Clinical Trial Of THR-B Agonist TERN-501.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.ternspharma.com/news-releases/news-release-details/terns-reports-positive-top-line-results-phase-1-proof-concept" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">November 9, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12 ">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Receives FDA Fast Track Designation for Efruxifermin
                                for the Treatment of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/10/19/2316901/0/en/Akero-Therapeutics-Receives-FDA-Fast-Track-Designation-for-Efruxifermin-EFX-for-the-Treatment-of-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">October 19, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Initiation Of 12-Week Phase 1b Trial Of Pemvidutide In Subjects With Non-Alcoholic Fatty Liver Disease.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-initiation-12-week-phase-1b-trial" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">October 4, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/lilly.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Lilly's tirzepatide led to greater improvements in liver fat content compared to insulin degludec in adults with type 2 diabetes in SURPASS-3 MRI sub-study.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="http://lilly.mediaroom.com/2021-09-30-Lillys-tirzepatide-led-to-greater-improvements-in-liver-fat-content-compared-to-insulin-degludec-in-adults-with-type-2-diabetes-in-SURPASS-3-MRI-sub-study" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 30, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">All Endpoints Met in Hepion Pharmaceuticals Drug-Drug Interaction Study
                                with CRV431.
                            </p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/09/29/2305435/0/en/All-Endpoints-Met-in-Hepion-Pharmaceuticals-Drug-Drug-Interaction-Study-with-CRV431.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 29, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Positive Results From 12-Week Phase 1 Clinical Trial Of ALT-801 (Pemvidutide) In Overweight And Obese Volunteers.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-results-12-week-phase-1-clinical" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 28, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/inventiva.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Inventiva announces FDA decision that Fast Track
                                designation granted to lanifibranor in NASH encompasses
                                the treatment of NASH with compensated cirrhosis.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://inventivapharma.com/wp-content/uploads/2021/09/Inventiva-PR-Fast-Track-EN-21092021.pdf" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 21, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/inventiva.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Inventiva announces the initiation of its pivotal Phase III
                                clinical trial evaluating lanifibranor in NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://inventivapharma.com/wp-content/uploads/2021/09/Inventiva-PR-Initiation-NATiV3-EN-08092021.pdf" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">September 8, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/89bio.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">89bio Completed Target Enrollment in Histology Cohort to Evaluate
                                BIO89-100 for the Treatment of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2021/08/02/2272848/0/en/89bio-Completed-Target-Enrollment-in-Histology-Cohort-to-Evaluate-BIO89-100-for-the-Treatment-of-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">August 2, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/sagimet.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Published Results from Sagimet's FASCINATE-1 Phase 2a Trial Demonstrate FASN Inhibitor TVB-2640's Ability to Significantly Reduce Excess Liver Fat.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.sagimet.com/news-releases/news-release-details/published-results-sagimets-fascinate-1-phase-2a-trial" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">July 26, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2A
                                AMBITION NASH Trial; All Primary Endpoints Achieved.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/07/13/2261922/0/en/Hepion-Pharmaceuticals-Announces-Positive-Topline-Data-from-Phase-2a-AMBITION-NASH-Trial-All-Primary-Endpoints-Achieved.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">July 13, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/madrigal.png" class="img-fluid" width="200px">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Madrigal Pharmaceuticals Completes Enrollment of the 52 Week Liver
                                Biopsy Patient Population in the Phase 3 MAESTRO-NASH Study.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/06/30/2255465/0/en/Madrigal-Pharmaceuticals-Completes-Enrollment-of-the-52-Week-Liver-Biopsy-Patient-Population-in-the-Phase-3-MAESTRO-NASH-Study-of-Resmetirom.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 30, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/altimmune.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Altimmune Announces Positive Interim Data From ALT-801 Phase 1 Trial In Overweight And Obese Volunteers.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.altimmune.com/news-releases/news-release-details/altimmune-announces-positive-interim-data-alt-801-phase-1-trial" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 16, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/terns.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Terns Reports Positive Top-Line Results From P2A LIFT Study of FXR Agonist TERN-101 In Patients With NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.ternspharma.com/news-releases/news-release-details/terns-reports-positive-top-line-results-phase-2a-lift-study-fxr" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 14, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/89bio.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">89bio Initiates Phase 2B ENLIVEN Trial of BIO89-100 for the Treatment
                                of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/en/news-release/2021/06/10/2245247/0/en/89bio-Initiates-Phase-2b-ENLIVEN-Trial-of-BIO89-100-for-the-Treatment-of-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">June 10, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/ngm.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">NGM Bio Reports Topline Results from 24-Week Phase 2b ALPINE 2/3 Study of Aldafermin in NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.ngmbio.com/news-releases/news-release-details/ngm-bio-reports-topline-results-24-week-phase-2b-alpine-23-study" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">May 24, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/hepion.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2A
                                AMBITION Clinical Trial of CRV431 for the Treatment of Advanced NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/05/06/2224420/0/en/Hepion-Pharmaceuticals-Completes-Final-Patient-Recruitment-in-Phase-2a-AMBITION-Clinical-Trial-of-CRV431-for-the-Treatment-of-Advanced-NASH.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">May 6, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Announces First Patient Randomized for Dosing in
                                Phase 2B Study of Efruxifermin in F2/F3 NASH Patients (HARMONY).</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/03/23/2197633/0/en/Akero-Therapeutics-Announces-First-Patient-Randomized-for-Dosing-in-Phase-2b-Study-of-Efruxifermin-EFX-in-F2-F3-NASH-Patients-HARMONY.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 23, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Announces Positive Histological Improvements: Cirrhotic NASH (F4)
                                Patients after 16 Weeks in Extension Cohort C.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/03/22/2197196/0/en/Akero-Announces-Positive-Histological-Improvements-in-Cirrhotic-NASH-F4-Patients-after-16-Weeks-in-Extension-Cohort-C.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 22, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics to Announce New Data from an Evaluation of
                                Efruxifermin (EFX) in Cirrhotic NASH (F4) Patients.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.globenewswire.com/news-release/2021/03/22/2196712/0/en/Akero-Therapeutics-to-Announce-New-Data-from-an-Evaluation-of-Efruxifermin-EFX-in-Cirrhotic-NASH-F4-Patients.html" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 22, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/novo.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Gilead Sciences and Novo Nordisk expand NASH clinical collaboration.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=51246" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 21, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/sagimet.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Sagimet Biosciences Receives Fast Track Designation from U.S. Food and Drug Administration for FASN Inhibitor TVB-2640 in NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.sagimet.com/news-releases/news-release-details/sagimet-biosciences-receives-fast-track-designation-us-food-and" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 16, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/sagimet.jpeg" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">FASN Inhibitor ASC40 Demonstrates Positive Phase 2 Topline Clinical Results from China Cohort of Patients with NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.sagimet.com/news-releases/news-release-details/fasn-inhibitor-asc40-demonstrates-positive-phase-2-topline" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">March 8, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/akero.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Akero Therapeutics Initiates Phase 2B HARMONY Study of Efruxifermin
                                (EFX) for the Treatment of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.akerotx.com/news-releases/news-release-details/akero-therapeutics-initiates-phase-2b-harmony-study-efruxifermin" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">February 24, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card shadow">
                        <img src="images/terns.png" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">Terns Announces FDA Clearance Of Investigational New Drug Application For First-In-Human P1 Trial Of TERN-501, Its THR-BETA Agonist In Development For The Treatment Of NASH.</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="https://ir.ternspharma.com/news-releases/news-release-details/terns-announces-fda-clearance-investigational-new-drug-ind" class="btn btn-primary w-25" target="_blank">Read</a>
                                <small class="text-body-secondary">January 19, 2021</small>
                            </div>
                        </div>
                    </div>
                </div>

                <!-- <div class="col-lg-4 col-md-6 col-12">
                    <div class="card border-primary d-flex align-items-center article-card">
                        <img src="#" class="img-fluid">
                        <div class="card-body text-center d-flex flex-column justify-content-between">
                            <p class="card-text">#</p>
                            <div class="d-flex justify-content-between align-items-center">
                                <a href="#" class="btn btn-primary w-25" target="_blank">#</a>
                                <small class="text-body-secondary">#</small>
                            </div>
                        </div>
                    </div>
                </div> -->

            </div>
        </div>
    </div>

    <footer class="py-3 mt-5 mb-3">
        <ul class="nav justify-content-center border-bottom pb-3 mb-3">
            <li class="nav-item"><a href="index.html" class="nav-link px-2 text-body-secondary">Hepion</a></li>
            <li class="nav-item"><a href="about.html" class="nav-link px-2 text-body-secondary">CRV431</a></li>
            <li class="nav-item"><a href="article.html" class="nav-link px-2 text-body-secondary">Article</a></li>
            <li class="nav-item"><a href="landscape.html" class="nav-link px-2 text-body-secondary">Landscape</a></li>
            <li class="nav-item"><a href="result.html" class="nav-link px-2 text-body-secondary">Data</a></li>
        </ul>
        <p class="text-center text-body-secondary">© 2023 CapriceYuri</p>
    </footer>

</body>

</html>